The American Cancer Society puts 16% of contributions into cancer research, according to its Annual Report. CureLauncher is the new way to put 91% of contributions directly into new cancer treatments....
(PRWeb December 05, 2012)
Read the full story at http://www.prweb.com/releases/cureLauncher/New_Cancer_Treatment/prweb10205696.htm
RiboMed Biotechnologies Inc., a leading Epigenetics-Based Diagnostics company, today announced that the U.S. Patent and Trademark Office has issued three additional patents covering the use of their...
(PRWeb December 05, 2012)
Read the full story at http://www.prweb.com/releases/2012/12/prweb10199227.htm
Integrated linear actuator incorporates linear servo motor with precision feedback and bearing system.
(PRWeb December 05, 2012)
Read the full story at http://www.prweb.com/releases/Linear_Actuator/Rotary_Table/prweb10178786.htm
The developed technology will provide autonomous robots with advanced vision capabilities for use in military and search-and-rescue operations.
(PRWeb December 05, 2012)
Read the full story at http://www.prweb.com/releases/2012/12/prweb10204073.htm
Revolutionary 3D MR Fusion technology BioJet™ chosen for its ability to improve clinical information and enhance patient outcomes
(PRWeb December 04, 2012)
Read the full story at http://www.prweb.com/releases/2012/12/prweb10198618.htm
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments